Molecular diagnosis of tumor refers to the molecular biological diagnosis technology with nucleic acid or protein as the core, which is an important method for early diagnosis of tumor.
The global Oncology Based Molecular Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Oncology Based Molecular Diagnostics, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncology Based Molecular Diagnostics, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Oncology Based Molecular Diagnostics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Based Molecular Diagnostics sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oncology Based Molecular Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Oncology Based Molecular Diagnostics sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Becton Dickinson
Cepheid
Dako
Danaher Corporation
Gen Probe(Hologic)
Roche Diagnostics
Siemens Healthcare
Segment by Type
PCR
Multiplex PCR
In Situ Hybridization
Isothermal Nucleic Acid Amplification Technology (INAAT)
Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Oncology Based Molecular Diagnostics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Oncology Based Molecular Diagnostics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Based Molecular Diagnostics sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Oncology Based Molecular Diagnostics Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Oncology Based Molecular Diagnostics 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 PCR
1.2.3 Multiplex PCR
1.2.4 In Situ Hybridization
1.2.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
1.3 麻豆原创 by Application
1.3.1 Global Oncology Based Molecular Diagnostics 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Cervical Cancer
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncology Based Molecular Diagnostics Sales Estimates and Forecasts 2019-2030
2.2 Global Oncology Based Molecular Diagnostics Revenue by Region
2.2.1 Global Oncology Based Molecular Diagnostics Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Oncology Based Molecular Diagnostics Revenue by Region (2019-2024)
2.2.3 Global Oncology Based Molecular Diagnostics Revenue by Region (2025-2030)
2.2.4 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Oncology Based Molecular Diagnostics Sales Estimates and Forecasts 2019-2030
2.4 Global Oncology Based Molecular Diagnostics Sales by Region
2.4.1 Global Oncology Based Molecular Diagnostics Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Oncology Based Molecular Diagnostics Sales by Region (2019-2024)
2.4.3 Global Oncology Based Molecular Diagnostics Sales by Region (2025-2030)
2.4.4 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Oncology Based Molecular Diagnostics Sales by Manufacturers
3.1.1 Global Oncology Based Molecular Diagnostics Sales by Manufacturers (2019-2024)
3.1.2 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oncology Based Molecular Diagnostics in 2023
3.2 Global Oncology Based Molecular Diagnostics Revenue by Manufacturers
3.2.1 Global Oncology Based Molecular Diagnostics Revenue by Manufacturers (2019-2024)
3.2.2 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oncology Based Molecular Diagnostics Revenue in 2023
3.3 Global Key Players of Oncology Based Molecular Diagnostics, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Oncology Based Molecular Diagnostics Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Oncology Based Molecular Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oncology Based Molecular Diagnostics, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oncology Based Molecular Diagnostics, Product Offered and Application
3.8 Global Key Manufacturers of Oncology Based Molecular Diagnostics, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Oncology Based Molecular Diagnostics Sales by Type
4.1.1 Global Oncology Based Molecular Diagnostics Historical Sales by Type (2019-2024)
4.1.2 Global Oncology Based Molecular Diagnostics Forecasted Sales by Type (2025-2030)
4.1.3 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Oncology Based Molecular Diagnostics Revenue by Type
4.2.1 Global Oncology Based Molecular Diagnostics Historical Revenue by Type (2019-2024)
4.2.2 Global Oncology Based Molecular Diagnostics Forecasted Revenue by Type (2025-2030)
4.2.3 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Oncology Based Molecular Diagnostics Price by Type
4.3.1 Global Oncology Based Molecular Diagnostics Price by Type (2019-2024)
4.3.2 Global Oncology Based Molecular Diagnostics Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Oncology Based Molecular Diagnostics Sales by Application
5.1.1 Global Oncology Based Molecular Diagnostics Historical Sales by Application (2019-2024)
5.1.2 Global Oncology Based Molecular Diagnostics Forecasted Sales by Application (2025-2030)
5.1.3 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Oncology Based Molecular Diagnostics Revenue by Application
5.2.1 Global Oncology Based Molecular Diagnostics Historical Revenue by Application (2019-2024)
5.2.2 Global Oncology Based Molecular Diagnostics Forecasted Revenue by Application (2025-2030)
5.2.3 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Oncology Based Molecular Diagnostics Price by Application
5.3.1 Global Oncology Based Molecular Diagnostics Price by Application (2019-2024)
5.3.2 Global Oncology Based Molecular Diagnostics Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Oncology Based Molecular Diagnostics 麻豆原创 Size by Type
6.1.1 US & Canada Oncology Based Molecular Diagnostics Sales by Type (2019-2030)
6.1.2 US & Canada Oncology Based Molecular Diagnostics Revenue by Type (2019-2030)
6.2 US & Canada Oncology Based Molecular Diagnostics 麻豆原创 Size by Application
6.2.1 US & Canada Oncology Based Molecular Diagnostics Sales by Application (2019-2030)
6.2.2 US & Canada Oncology Based Molecular Diagnostics Revenue by Application (2019-2030)
6.3 US & Canada Oncology Based Molecular Diagnostics 麻豆原创 Size by Country
6.3.1 US & Canada Oncology Based Molecular Diagnostics Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Oncology Based Molecular Diagnostics Sales by Country (2019-2030)
6.3.3 US & Canada Oncology Based Molecular Diagnostics Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oncology Based Molecular Diagnostics 麻豆原创 Size by Type
7.1.1 Europe Oncology Based Molecular Diagnostics Sales by Type (2019-2030)
7.1.2 Europe Oncology Based Molecular Diagnostics Revenue by Type (2019-2030)
7.2 Europe Oncology Based Molecular Diagnostics 麻豆原创 Size by Application
7.2.1 Europe Oncology Based Molecular Diagnostics Sales by Application (2019-2030)
7.2.2 Europe Oncology Based Molecular Diagnostics Revenue by Application (2019-2030)
7.3 Europe Oncology Based Molecular Diagnostics 麻豆原创 Size by Country
7.3.1 Europe Oncology Based Molecular Diagnostics Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Oncology Based Molecular Diagnostics Sales by Country (2019-2030)
7.3.3 Europe Oncology Based Molecular Diagnostics Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oncology Based Molecular Diagnostics 麻豆原创 Size
8.1.1 China Oncology Based Molecular Diagnostics Sales (2019-2030)
8.1.2 China Oncology Based Molecular Diagnostics Revenue (2019-2030)
8.2 China Oncology Based Molecular Diagnostics 麻豆原创 Size by Application
8.2.1 China Oncology Based Molecular Diagnostics Sales by Application (2019-2030)
8.2.2 China Oncology Based Molecular Diagnostics Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oncology Based Molecular Diagnostics 麻豆原创 Size by Type
9.1.1 Asia Oncology Based Molecular Diagnostics Sales by Type (2019-2030)
9.1.2 Asia Oncology Based Molecular Diagnostics Revenue by Type (2019-2030)
9.2 Asia Oncology Based Molecular Diagnostics 麻豆原创 Size by Application
9.2.1 Asia Oncology Based Molecular Diagnostics Sales by Application (2019-2030)
9.2.2 Asia Oncology Based Molecular Diagnostics Revenue by Application (2019-2030)
9.3 Asia Oncology Based Molecular Diagnostics Sales by Region
9.3.1 Asia Oncology Based Molecular Diagnostics Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Oncology Based Molecular Diagnostics Revenue by Region (2019-2030)
9.3.3 Asia Oncology Based Molecular Diagnostics Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Sales by Country
10.3.1 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Oncology Based Molecular Diagnostics Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Information
11.1.2 Abbott Laboratories Overview
11.1.3 Abbott Laboratories Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Abbott Laboratories Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Abbott Laboratories Recent Developments
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Information
11.2.2 Bayer Healthcare Overview
11.2.3 Bayer Healthcare Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Bayer Healthcare Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Bayer Healthcare Recent Developments
11.3 Becton Dickinson
11.3.1 Becton Dickinson Company Information
11.3.2 Becton Dickinson Overview
11.3.3 Becton Dickinson Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Becton Dickinson Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Becton Dickinson Recent Developments
11.4 Cepheid
11.4.1 Cepheid Company Information
11.4.2 Cepheid Overview
11.4.3 Cepheid Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Cepheid Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Cepheid Recent Developments
11.5 Dako
11.5.1 Dako Company Information
11.5.2 Dako Overview
11.5.3 Dako Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Dako Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Dako Recent Developments
11.6 Danaher Corporation
11.6.1 Danaher Corporation Company Information
11.6.2 Danaher Corporation Overview
11.6.3 Danaher Corporation Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Danaher Corporation Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Danaher Corporation Recent Developments
11.7 Gen Probe(Hologic)
11.7.1 Gen Probe(Hologic) Company Information
11.7.2 Gen Probe(Hologic) Overview
11.7.3 Gen Probe(Hologic) Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Gen Probe(Hologic) Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Gen Probe(Hologic) Recent Developments
11.8 Roche Diagnostics
11.8.1 Roche Diagnostics Company Information
11.8.2 Roche Diagnostics Overview
11.8.3 Roche Diagnostics Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Roche Diagnostics Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Roche Diagnostics Recent Developments
11.9 Siemens Healthcare
11.9.1 Siemens Healthcare Company Information
11.9.2 Siemens Healthcare Overview
11.9.3 Siemens Healthcare Oncology Based Molecular Diagnostics Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Siemens Healthcare Oncology Based Molecular Diagnostics Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Siemens Healthcare Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oncology Based Molecular Diagnostics Industry Chain Analysis
12.2 Oncology Based Molecular Diagnostics Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oncology Based Molecular Diagnostics Production Mode & Process
12.4 Oncology Based Molecular Diagnostics Sales and 麻豆原创ing
12.4.1 Oncology Based Molecular Diagnostics Sales Channels
12.4.2 Oncology Based Molecular Diagnostics Distributors
12.5 Oncology Based Molecular Diagnostics Customers
13 麻豆原创 Dynamics
13.1 Oncology Based Molecular Diagnostics Industry Trends
13.2 Oncology Based Molecular Diagnostics 麻豆原创 Drivers
13.3 Oncology Based Molecular Diagnostics 麻豆原创 Challenges
13.4 Oncology Based Molecular Diagnostics 麻豆原创 Restraints
14 Key Findings in The Global Oncology Based Molecular Diagnostics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Abbott Laboratories
Bayer Healthcare
Becton Dickinson
Cepheid
Dako
Danaher Corporation
Gen Probe(Hologic)
Roche Diagnostics
Siemens Healthcare
听
听
*If Applicable.
